The latest market intelligence, insights and interviews covering the cell and gene therapy industry's most pressing challenges, from translation to automation, manufacturing to market access, viral vectors to bioreactors.
This is the final post in a series of five blogs summarising key discussion points and outcomes from the latest Automation Special Interest Group (SIG) sessions, held in June 2021.
